- Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line
-
Makol A, Kaur H, Sharma S, Kanthaje S, Kaur R, Chakraborti A
- KMID: 2501315
- Clin Mol Hepatol.
- 2020 Jan;26(1):45-53.
- doi: 10.3350/cmh.2019.0031
Background/Aims: Hepatocellular carcinoma (HCC) is the most common liver cancer with high mortality rate in patients suffering from liver diseases. The drug of choice used in advanced-stage of HCC is... -
- CITED
-
- Close
- SHARE
-
- Close
